Strategy in advanced castration-resistant prostate cancer

被引:0
|
作者
Gross-Goupil, Marine [1 ,2 ]
Roca, Sophie [1 ]
Pasticier, Gilles [3 ]
Ravaud, Alain [1 ,2 ]
机构
[1] CHU Bordeaux, Hop St Andre, Med Oncol Serv, F-33075 Bordeaux, France
[2] Univ Bordeaux 2, F-33076 Bordeaux, France
[3] CHU Bordeaux, Hop Pellegrin, Serv Urol, F-33075 Bordeaux, France
关键词
prostate cancer; hormonotherapy; chemotherapy; immunotherapy; targeted therapy; MITOXANTRONE PLUS PREDNISONE; PHASE-III TRIAL; SIPULEUCEL-T; ANTIANDROGEN WITHDRAWAL; 2ND-LINE CHEMOTHERAPY; DOCETAXEL; ESTRAMUSTINE; EFFICACY; ABIRATERONE; SURVIVAL;
D O I
10.1684/bdc.2012.1562
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
If androgen deprivation, chemical with [H-RH analogs or surgical with bilateral orchiectomy, still remains the stone edge of treatment of prostate cancer, in the metastatic setting, this hormonosensitivity, most of the time long, finally move on in hormonal-failure. If rare changes in the therapeutic strategy have been achieved in this setting since 2004 and the arrival of docetaxel, it is the global perception of the disease that has been modified and the definition of one specific entity: the castrate-resistant prostate cancer. This new definition and the changes of design and end-points of clinical trials testing new agents with strong recruitment during the past years have conducted to a real revolution in the management of castrate-refractory prostate cancer. The place of secondary hormonal manipulations, such as withdrawal of the anti-androgen, oestrogen or ketoconazole, still exists for a selected group of patients. In case of aggressive disease and symptoms, chemotherapy should be selected, docetaxel, in a three weeks schedule, and may be combined with Estracyt. It is time to consider the revolution of the post-chemotherapy setting with the arrival of two new drugs; a cytotoxic one, the cabazitaxel and hormonal for the second one, the abiraterone acetate. The place of the immunotherapy with the sipuleucel-T may be more difficult to precise, especially in Europe, even if it has been finally indicated in the United States in the metastatic setting. Concerning bone metastasis, zoledronic acid was during a long time the only bone-targeted agent, effective in reducing the incidence of skeletal related events, and was recently exceeded by the denosumab, an anti-RANK ligand. Finally, let us hope that other changes will be achieved in the near future, with the cabazitaxel-docetaxel confrontation in the first-line setting, and the introduction of the abiraterone acetate before chemotherapy with docetaxel, already tested in ongoing trials.
引用
收藏
页码:S37 / S45
页数:9
相关论文
共 50 条
  • [21] Sequencing Treatment for Castration-Resistant Prostate Cancer
    Handy, Catherine E.
    Antonarakis, Emmanuel S.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (12)
  • [22] Current, new and novel therapy for castration-resistant prostate cancer
    Gaya, Josep M.
    Ahallal, Youness
    Sanchez-Salas, Rafael
    Barret, Eric
    Rozet, Francois
    Macek, Marc Galiano Peter
    Durand, Matthieu
    Cerruti, Jennifer
    Prapotnich, Dominique
    Ropert, Stanislas
    Bennamoun, Mostefa
    Cathelineau, Xavier
    EXPERT REVIEW OF ANTICANCER THERAPY, 2013, 13 (07) : 819 - 827
  • [23] The role of abiraterone in the management of metastatic castration-resistant prostate cancer
    Rawlinson, Alex
    Mohammed, Aza
    Beatty, John
    Bell, Richard
    Miller, Marek
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (04) : 429 - 437
  • [24] The changing landscape in the treatment of metastatic castration-resistant prostate cancer
    El-Amm, Joelle
    Aragon-Ching, Jeanny B.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2013, 5 (01) : 25 - 40
  • [25] Novel Molecular Targets for the Therapy of Castration-Resistant Prostate Cancer
    Agarwal, Neeraj
    Sonpavde, Guru
    Sternberg, Cora N.
    EUROPEAN UROLOGY, 2012, 61 (05) : 950 - 960
  • [26] Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer
    Abouharb, Sausan
    Corn, Paul G.
    CURRENT ONCOLOGY REPORTS, 2013, 15 (03) : 217 - 223
  • [27] Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer
    Leibowitz-Amit, Raya
    Templeton, Arnoud J.
    Alibhai, Shabbir M.
    Knox, Jennifer J.
    Sridhar, Srikala S.
    Tannock, Ian F.
    Joshua, Anthony M.
    JOURNAL OF GERIATRIC ONCOLOGY, 2015, 6 (01) : 23 - 28
  • [28] Prevalence of Measurable Disease in Metastatic Castration-resistant Prostate Cancer
    Sonpavde, Guru
    Madan, Ankit
    Baker, Mary K.
    May, Jori E.
    Naik, Gurudatta
    Bae, Sejong
    CLINICAL GENITOURINARY CANCER, 2017, 15 (05) : 534 - 539
  • [29] New Strategies for Medical Management of Castration-Resistant Prostate Cancer
    Asmane, Irene
    Ceraline, Jocelyn
    Duclos, Brigitte
    Rob, Lynn
    Litique, Valere
    Barthelemy, Philippe
    Bergerat, Jean-Pierre
    Dufour, Patrick
    Kurtz, Jean-Emmanuel
    ONCOLOGY, 2011, 80 (1-2) : 1 - 11
  • [30] Advances in systemic therapies for metastatic castration-resistant prostate cancer
    Pant, Manish K.
    Abughaban, Ahmed
    Aragon-Ching, Jeanny B.
    FUTURE ONCOLOGY, 2014, 10 (14) : 2213 - 2226